Open Access
Licensing instead of fueling: Glutamine synthetase promotes mitotic progression via a non-metabolic mechanism
Vis Cancer Med, 4 (2023) 3
Published online: 17 January 2023
Visualized Cancer Medicine
Visualized Cancer Medicine is an interdisciplinary and peer-reviewed journal, which publishes the advances in basic, translational, and clinical studies on cancer biology, cancer prevention, cancer screening and diagnosis, cancer treatments, and cancer patient rehabilitation, with an emphasis on videos presenting the natural process, interventional procedure, and spatial alteration of the studied objects.
Visualized Cancer Medicine is the official journal of the Society of Tumor Microenvironment, China Anti-Cancer Association.
This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
-
-
Open AccessReview
Integrin α6 targeted cancer imaging and therapy
Vis Cancer Med, 4 (2023) 4Published online: 13 January 2023 -
Open AccessReview
Functions of glutaminyl cyclase and its isoform in diseases
Vis Cancer Med, 4 (2023) 1Published online: 06 January 2023 -
Open Access
WTX beyond WNT signaling pathway
Vis Cancer Med, 4 (2023) 2Published online: 06 January 2023 -
Open Access
Benefits of precision medicine in lung cancer: experience from a single institution
Vis Cancer Med, 3 (2022) 4Published online: 21 October 2022 -
Open AccessReview
CBP/p300 bromodomain: new promising epigenetic target
Vis Cancer Med, 3 (2022) 3Published online: 12 September 2022 -
Open AccessEditorial
Another treatment option for locally advanced hepatocellular carcinoma: Interventional arterial infusion of FOLFOX chemotherapy from the FOHAIC-1 study
Vis Cancer Med, 3 (2022) E1Published online: 26 April 2022 -
Open AccessReview
MxA: a broadly acting effector of interferon-induced human innate immunity
Vis Cancer Med, 3 (2022) 2Published online: 06 April 2022
| 26 |
Open Access
Review
Functions of glutaminyl cyclase and its isoform in diseasesVis Cancer Med, 4 (2023) 1
Published online: 06 January 2023
|
| 23 |
Open Access
Review
CBP/p300 bromodomain: new promising epigenetic targetVis Cancer Med, 3 (2022) 3
Published online: 12 September 2022
|
| 17 |
Open Access
Review
Metastasis of nasopharyngeal carcinoma: What we know and do not knowVis Cancer Med, 2 (2021) 4
Published online: 11 August 2021
|
| 15 |
Open Access
Review
MxA: a broadly acting effector of interferon-induced human innate immunityVis Cancer Med, 3 (2022) 2
Published online: 06 April 2022
|
| 15 |
Open Access
Spatially-resolved proteomics and transcriptomics: An emerging digital spatial profiling approach for tumor microenvironmentVis Cancer Med, 2 (2021) 1
Published online: 03 March 2021
|
